Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipid management: past, present, and future

D J Betteridge1

  • 1Department of Medicine, Middlesex Hospital, London, UK.

British Journal of Clinical Practice. Supplement
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).

Diabetic medicine : a journal of the British Diabetic Association·2013
Same author

Thiazolidinediones and fracture risk in patients with Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2011
Same author

High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive.

Diabetes, obesity & metabolism·2011
Same author

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.

Diabetes, obesity & metabolism·2011
Same author

An Examination of Some Factors which Influence the Stability of in Vitro Platelet Responses.

Platelets·2010
Same author

Collagen-induced Platelet Activation In Vitro Increases Plasma Catecholamine Concentration.

Platelets·2010
Same journal

Treatment of dyslipidaemias with fluvastatin.

British journal of clinical practice. Supplement·2009
Same journal

Lipoprotein(a) as a marker for coronary heart disease.

British journal of clinical practice. Supplement·2009
Same journal

Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial.

British journal of clinical practice. Supplement·2009
Same journal

Risk factor management: the cardiologist's perspective.

British journal of clinical practice. Supplement·2009
Same journal

Fluvastatin in combination with other lipid-lowering agents.

British journal of clinical practice. Supplement·2009
Same journal

The patient at risk: who should we be treating?

British journal of clinical practice. Supplement·2009
See all related articles

Effective lipid disorder management is now possible with HMG-CoA reductase inhibitors, proven to reduce mortality. Widespread screening and treatment of high-risk individuals are crucial for public health, especially in the UK.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Public Health

Background:

  • Lipid disorders pose significant cardiovascular risks.
  • Therapeutic options in the 1990s allowed for effective patient management.
  • HMG-CoA reductase inhibitors represent a major therapeutic advance.

Purpose of the Study:

  • To highlight the impact of HMG-CoA reductase inhibitors on overall mortality.
  • To emphasize the need for improved screening and treatment strategies for high-risk individuals.
  • To discuss future directions in lipid management and atherogenesis research.

Main Methods:

  • Review of therapeutic advancements in lipid disorder treatment.
  • Analysis of the 4S study demonstrating mortality benefits.

Related Experiment Videos

  • Discussion of current challenges in implementing effective screening and treatment protocols.

    • Main Results:

    • HMG-CoA reductase inhibitors have demonstrated a significant reduction in overall mortality.
    • The 4S study provides robust evidence for the benefits of these inhibitors.
    • The UK shows a lag in the implementation of screening and treatment for high-risk patients.

    Conclusions:

    • Effective management of lipid disorders is achievable with current therapies.
    • There is an urgent need for better implementation of screening and treatment protocols.
    • Future research will focus on novel lipid targets and atherogenesis interventions.